HCAT Stock Analysis: Buy, Sell, or Hold?
HCAT - Health Catalyst, Inc Common Stock
$1.14
-0.02 (-1.72%)
▼
5d:
+3.64%
30d:
-41.54%
90d:
-52.3%
BUY
HIGH Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 06, 2026
Get Alerted When HCAT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: HCAT shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: HCAT shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: HCAT is currently trading at $1.14, which is considered oversold relative to its 30-day fair value range of $1.21 to $1.86. From a valuation perspective, the stock is trading at a premium (Forward PE: 7.3) compared to its historical average (6.2). At these levels, the market is pricing in 6.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HCAT is in a strong downtrend. Immediate support is located at $1.06, while resistance sits at $1.29.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1.96 (+69.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HCAT is in a strong downtrend. Immediate support is located at $1.06, while resistance sits at $1.29.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1.96 (+69.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.21 -
$1.86
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
78.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 69.3% below Wall St target ($1.96)
- NEUTRAL: Trading at premium valuation - market expects 6.0% growth which is achievable
Fair Price Analysis
30-Day Fair Range
$1.21 -
$1.86
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.06
Resistance Level
$1.29
Current Trend
Strong Downtrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.32
Wall Street Target
$1.96
(+69.3%)
Revenue Growth (YoY)
-6.2%
Profit Margin
-57.2%
Valuation Premium vs History
+6.0% premium
PE vs Historical
7.3 vs 6.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.0%
(market-implied from PE analysis)
1-Year Target
$1.23
(+6%)
2-Year Target
$1.30
(+12%)
3-Year Target
$1.38
(+19%)
3-Yr Target (if PE normalizes)
(PE: 7→6)
PE COMPRESSION
$1.17
(+1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 20.6%)
$6.22
(+436%)
Base:
(SPY PE: 7.3, Growth: 20.6%)
$2.04
(+76%)
Bear:
(PE: 6.2, Growth: 20.6%)
$1.72
(+49%)
Share & Embed Analysis
Last updated: April 02, 2026 10:39 AM ET
Data refreshes hourly during market hours. Next update: 11:39 AM
Data refreshes hourly during market hours. Next update: 11:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HCAT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Benjamin Landry
SELL
27425 shares
2025-12-05
Julie Larson-Green
SELL
47997 shares
2025-12-04
Top Rated Health Information Services Stocks
Top-rated stocks in Health Information Services by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VEEV
Veeva Systems Inc Class A |
BUY
32 analysts |
$271 | 54 HOLD |
|
PRVA
Privia Health Group Inc |
STRONG BUY
21 analysts |
$32 | 61 BUY |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$90 | 65 BUY |
|
HQY
HealthEquity Inc |
STRONG BUY
14 analysts |
$112 | 66 BUY |
|
PHR
Phreesia Inc |
STRONG BUY
15 analysts |
$28 | 53 HOLD |
Advanced HCAT Option Strategies
Professional options setups generated by AI based on today's HCAT price and gamma walls.
